Kiniksa Pharmaceuticals (KNSA) Scheduled to Post Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is scheduled to post its quarterly earnings results before the market opens on Tuesday, April 23rd. Analysts expect Kiniksa Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.15. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. The firm had revenue of $83.40 million for the quarter, compared to analysts’ expectations of $72.31 million. On average, analysts expect Kiniksa Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kiniksa Pharmaceuticals Trading Down 2.9 %

NASDAQ:KNSA traded down $0.51 during trading hours on Wednesday, hitting $16.95. 389,307 shares of the stock traded hands, compared to its average volume of 400,750. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 94.17 and a beta of 0.27. The firm has a 50 day moving average price of $19.61 and a 200 day moving average price of $17.97. Kiniksa Pharmaceuticals has a fifty-two week low of $10.65 and a fifty-two week high of $22.09.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. TheStreet raised Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Wedbush reissued an “outperform” rating and issued a $30.00 price target (up from $28.00) on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, April 2nd.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,659 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $21.45, for a total value of $207,185.55. Following the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at $377,262.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,659 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $21.45, for a total value of $207,185.55. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares in the company, valued at $377,262.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sanj K. Patel sold 12,742 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the sale, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at $1,517,065.06. The disclosure for this sale can be found here. Insiders sold 33,109 shares of company stock valued at $709,929 in the last quarter. Company insiders own 54.23% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. grew its holdings in Kiniksa Pharmaceuticals by 5.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 909,212 shares of the company’s stock valued at $15,948,000 after purchasing an additional 43,430 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Kiniksa Pharmaceuticals by 9.5% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 18,784 shares of the company’s stock worth $329,000 after buying an additional 1,626 shares during the period. Virtus ETF Advisers LLC grew its stake in Kiniksa Pharmaceuticals by 3.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 19,132 shares of the company’s stock valued at $336,000 after buying an additional 671 shares during the last quarter. Legal & General Group Plc raised its holdings in Kiniksa Pharmaceuticals by 3.9% in the 4th quarter. Legal & General Group Plc now owns 25,068 shares of the company’s stock worth $440,000 after acquiring an additional 944 shares during the period. Finally, Royal Bank of Canada lifted its position in Kiniksa Pharmaceuticals by 64.3% during the 4th quarter. Royal Bank of Canada now owns 11,588 shares of the company’s stock worth $203,000 after acquiring an additional 4,535 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.